A retrospective study to understand the clinical role and utility of twice daily dose of Bepotastine in patients with irritation and internal swelling of nose

BepotAstine in symptomAtic Rhinits: a drug utilization surveillance study (BAAR) - BAAR

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2018/09/015582

Enrollment

3800

Registered

2018-09-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J00- Acute nasopharyngitis [common cold] Health Condition 2: J309- Allergic rhinitis, unspecified

Interventions

Intervention1: Bepotastine tablet: 10 mg twice daily orally for up to 4 weeks Control Intervention1: NA: NA

Eligibility

Inclusion criteria

Inclusion criteria: Patients with High risk or symptomatic rhinitis

Exclusion criteria

Exclusion criteria: Patients with follow up records of less than one visit

Design outcomes

Primary

Measure	Time frame
4 weeks case records will be analyzed: Details on T5SS scores for baseline & next follow-up visitTimepoint: 4 weeks	—

Secondary

Measure	Time frame
Treatment Emergent Adverse Events (TEAEs) or Safety analyses at 4 weeksTimepoint: 4 weeks	—

Countries

India

Contacts

Public ContactDr K Krishnaprasad

Glenmark Pharmaceuticals Ltd.

K.Krishna.Prasad@glenmarkpharma.com9820806811

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026